Sage Pharmaceuticals Inc – FDA CRL

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Sarfez Pharmaceuticals Inc. for its New Drug Application (NDA) 213218 for torsemide 20 mg and 60 mg, indicating the application cannot be approved in its current state. A significant issue arose from a recent inspection of a manufacturing facility, where unsatisfactory conditions were observed, demanding resolution before approval. Furthermore, the proposed Prescribing Information (PI) failed to conform to FDA content and format regulations (21 CFR 201.56(a) and (d), and 201.57), requiring extensive revisions to align with Physician Labeling Rule and Pregnancy and Lactation Labeling Rule guidelines, and submission in Structured Product Labeling (SPL) format. The FDA also requested the submission of draft carton and container labeling. Although the proprietary name "SOAANZ" was conditionally acceptable, it must be resubmitted with the full response. Crucially, a comprehensive safety update, as per 21 CFR 314.50(d)(5)(vi)(b), is required, detailing new clinical and nonclinical safety data, combined adverse event tabulations, and updated worldwide experience. Sarfez Pharmaceuticals Inc. must address all identified deficiencies and resubmit the application within one year.